Sample Size: 125,474 adults T2DM (61.0% of total sample, n = 76,524) 98.6% (n = 75,434) using GLP-1s as antidiabetic medications 1.4% (n = 1,090) using GLP-1s as antiobesity medications Without T2DM (39.0% of total sample, n = 48,950) 61.8% (n = 30,236) using GLP-1s off-label as antidiabetic medications 38.2% (n = 18,714) using GLP-1s specifically for weight management Data Source: Truveta Data Aggregated electronic health record (EHR) data from 30 U.S
Use an alcohol-free mouthwash
Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders
These include: Nausea (most frequent, often transient) Vomiting and diarrhoea Constipation Abdominal discomfort or bloating These symptoms typically diminish over 48 weeks as tolerance develops
Much attention is paid to blood and heart health, as well as gut health